Company intelligence / Profile preview

Cempra

Chapel Hill, North Carolina, United Statescempra.com ↗

Ownership: Private
Development stage: Other

Overview

Cempra developed novel antibiotics targeting drug-resistant bacteria. Its lead asset solithromycin completed two Phase III trials for CABP but faced FDA rejection due to safety concerns and manufacturing issues. Fusidic acid completed a successful Phase III study for ABSSSI. Radezolid was in early clinical development for acne vulgaris at the time of the Melinta merger. The company merged with Melinta Therapeutics in August 2017 to form a leading anti-infectives company focused on commercializing Baxdela and advancing these pipeline assets.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small moleculeMacrolide antibioticOxazolidinone antibiotic
Industry: Biotech

Partnerships

Toyama Chemical Co., Ltd./FUJIFILM Holdings Corporation – licensing rights for solithromycin in JapanBARDA – contract for pediatric development of solithromycin

Beyond the preview

Go deeper on Cempra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cempra.